REA Group has upped its bid for Rightmove to £6.1 billion. This values each Rightmove share at 770 pence, a 9.2% increase from the initial offer. Rightmove rose 3.0% today, while REA dropped 2.5%.
AstraZeneca reported that its breast cancer treatment, Dato-DXd, did not achieve statistical sig…
© MarketScreener.com 2024
AstraZeneca reported that its breast cancer treatment, Dato-DXd, did not achieve statistical sig…
© MarketScreener.com 2024